Putative innate immunity of antiatherogenic paraoxanase-2 via STAT5 signal transduction in HIV-1 infection of hematopoietic TF-1 cells and in SCID-Hu mice

Journal of Stem Cells

Volumn 5, Issue 1, 2010, Pages 43-48

  Yuan, Jinyun ^a   Devarajan, Asokan ^b   Moya Castro, Rosita ^a   Zhang, Menghua ^a   Evans, Stella ^a   Bourquard, Noam ^b,c   Dias, Peter ^a   Lacout, Catherine ^d   Vainchenker, William ^d   Reddy, Srinivasa T ^b,c   Koka, Prasad S ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

GM CSF starvation; HIV 1; Innate immunity; Paraoxonase 2; STAT5 phosphorylation; TF 1

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MEMBRANE PROTEIN; MESSENGER RNA; PARAOXANASE 2; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYMOCYTE;

ANIMALS; ANTIGENS, CD34; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BLOTTING, WESTERN; CARDIOTONIC AGENTS; CELLS, CULTURED; FETUS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; LIVER; MICE; MICE, SCID; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; THYMUS GLAND;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 78650486194     PISSN: 15568539     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Suresh DR, Annam V Pratibha K, Prasad BV, Total antioxidant capacity-a novel early bio-chemical marker of oxidative stress in HIV infected individuals. J. Biomed. Sci. 2009; 7: 16-61.
2. Ng CJ, Wadleigh DJ, Gangopadhyay A. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem 2001; 276:44444-44449.
3. Reddy ST, Wadleigh DJ, Grijalva VF. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 2001;21: 542-547
4. Mochizuki, H., Scherer, S.W., Xi, T., Nickle, D.C., Majer, M., Huizenga, J. J, Tsui, L.C., and Prochazka, M. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene, 1998; 213:149-157.
5. Boright A.P., Connelly, P.W., Brunt,J.H., Scherer, S.W., Tsui, L.C., Hegele, R.A. Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterties. Atherosclerosis. 2005; 139:131-136
6. Hegele, R.A., Harris, S. B., Connelly, P.W., Hanley, A. J., Tsui, L.C., Zinman, B., and Scherer, S. W. Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. Clin. Genet. 1998, 54: 394-399. (Pubitemid 28499786)
7. Mackness, B., Durrington, P.N., Abuashia, B., Boulton, A. J., Mackness, M. I. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin. Sci. (Lond.), 2000, 98: 355-363.
8. Busch,C.P., Ramdath, D.D., Ramsewak, S., and Hegele, R.A. Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. Pharmacogenetics, 1999, 9: 351-356.
9. Sanghera, D. K., Aston, C. E., Saha, N., and Kamboh, M. I. DNA Polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am. J. Hum.Genet. 1998, 62: 36-44.
10. Parra S, Alonso Villaverde C, Coll B, Ferre N, Marsillach J, Coll B, Ferre N, Marsillach J, Aragones G, Mackness M, Mackness B, Masana L, Joven J, Camps J. Serum paraoxonase-1 activity and concentration are influenced human immunodeficiency virus infection. Atherosclerosis 2007; 194(1): 175-180.
11. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic. Biol. Med.2005; 5: 38(2):153-
12. Koka PS, Fraser JK, Bryson Y, Bristol GC, Aldrovandi GM, Daar ES, Zack JA. Human immunodeficiency virus type 1 inhibits multilineage hematopoiesis in vivo. J. Virol 1998; 72: 5121-5127.
13. Koka PS, Jamieson BD, Brooks DG, Zack JA. Human immunodeficiency virus type-1 induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J. Virol. 1999; 73: 9089-9097.
14. Koka PS, Kitchen CM, Reddy ST. Targeting c-Mpl for revival of human immunodeficiency virus type 1-induced hematopoietic inhibition when CD34+ progenitor cells are re-engrafted into a fresh stromal Microenvironment in vivo. J. Virol. 2004; 78: 11385-11392.
15. Sundell IB, Koka PS. Chimeric SCID-hu Model as a Human Hematopoietic Stem Cell Host that Recapitulates the Effects of HIV-1 on Bone Marrow Progenitors in Infected Patients. J. Stem Cells 2006; 1(4): 283-300.
16. Zhang M, Poh TY, Louache F, Sundell IB, Yuan J, Evans S, Koka PS. Rescue of multi-lineage hematopoiesis during HIV-1 Infection by human c-mpl gene transfer and reconstitution of CD34+ progenitor cells in vivo. J. Stem Cells 2009; 4(3): 161-177.
17. Zhang M, Evans S, Yuan J, Ratner L, Koka PS. HIV-1 determinants of thrombocytopenia at the stage of CD34+ progenitor cell differentiation in vivo lie in the viral envelope gp120 V3 loop region. Virology 2010; in press.
18. Sundell IB, Halder R, Zhang M, Maricic I, Koka PS, Kumar V. Sulfatide administration leads to inhibition of HIV-1 replication and enhanced hematopoiesis. Accepted for Publication. J. Stem Cells, Volume 5, Issue 1, 2010.
19. Selliah N, Finkel TH. HIV-1 NL4-3, but not IIIB, inhibits JAK3/STAT5 activation in CD4(+) T cells. Virology. 2001; 286(2):412-21